Targeting triple-negative breast cancers with the Smac-mimetic birinapant

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Smac mimetics inhibit apoptosis (IAP) proteins to promote cancer cell death.
• Evaluating Smac mimetics, compound A and birinapant, in breast cancer models.

Purpose of the Study:

• Assess the efficacy of Smac mimetics in triple-negative breast cancer (TNBC).
• Investigate birinapant's activity in vivo and its potential to enhance chemotherapy response.

Main Methods:

• In vitro testing on TNBC and ER+ breast cancer cell lines, including patient-derived xenograft (PDX) models.
• In vivo studies using TNBC and ER+ breast cancer PDX models.
• Transcriptomic analysis of TCGA datasets to identify molecular signatures.

Main Results:

• Both Smac mimetics showed potent in vitro activity against TNBC cells.
• Birinapant demonstrated single-agent activity in TNBC PDX models and enhanced docetaxel response.
• TNBC tumors exhibited higher expression of genes related to Smac-mimetic-induced cell death compared to ER+ tumors.

Conclusions:

• Smac mimetics, particularly birinapant, are effective against TNBC.
• A molecular signature in TNBC predicts responsiveness to Smac mimetics.
• Birinapant warrants further clinical investigation for breast cancer patients with competent death receptor signaling pathways.